目的:探讨AGGF1(angiogenic factor with G and FHA domains 1)在乳腺癌中的表达及其与乳腺癌患者预后的意义。方法:利用免疫组织化学方法检测110例乳腺癌组织及配对癌旁正常组织AGGF1蛋白的表达,并分析其与临床病理指标的关系及对患者...目的:探讨AGGF1(angiogenic factor with G and FHA domains 1)在乳腺癌中的表达及其与乳腺癌患者预后的意义。方法:利用免疫组织化学方法检测110例乳腺癌组织及配对癌旁正常组织AGGF1蛋白的表达,并分析其与临床病理指标的关系及对患者预后的影响。结果:在乳腺癌组织中,AGGF1蛋白阳性45例(41%),AGGF1蛋白阴性65例(59%);配对癌旁正常组织中,AGGF1蛋白阳性15例(13.6%),AGGF1蛋白阴性95例(86.4%);AGGF1在乳腺癌组织的表达明显高于配对癌旁正常组织,差异有统计学意义(P<0.05)。AGGF1蛋白表达与患者年龄、肿瘤大小、TNM分期、淋巴结转移等无相关性(P>0.05);AGGF1蛋白表达与ER,PR,HER-2,增殖指数(Ki-67)等有相关性(P<0.05)。生存分析显示,AGGF1蛋白阳性表达患者的无病生存期(disease-free survival,DFS)与总生存期(overall-survival,OS)明显差于AGGF1蛋白阴性表达者,差异有统计学意义(P<0.05)。多因素COX比例风险回归模型分析发现:AGGF1蛋白阳性表达与乳腺癌患者的预后相关,为预后的独立预测因子。结论:在乳腺癌组织中,AGGF1蛋白阳性表达,与患者不良预后相关,可作为乳腺癌患者预后预测的指标,也有可能为潜在的治疗靶点。展开更多
Liver injury represents a continuum of pathophysiological processes involving a complex interplay between hepatocytes, macrophages, and hepatic stellate cells. The mechanism whereby these intercellular interactions co...Liver injury represents a continuum of pathophysiological processes involving a complex interplay between hepatocytes, macrophages, and hepatic stellate cells. The mechanism whereby these intercellular interactions contribute to liver injury and fibrosis is not completely understood. We report here that angiogenic factor with G patch and FHA domains 1(Aggfl) was downregulated in the livers of cirrhotic patients compared to healthy controls and in primary hepatocytes in response to carbon tetrachloride(CC14) stimulation. Overexpression of Aggfl attenuated macrophage chemotaxis. Aggfl interacted with NF-κB to block its binding to the Ccl2 gene promoter and repressed Ccl2 transcription in hepatocytes. Macrophages cultured in the conditioned media collected from Aggfloverexpressing hepatocytes antagonized HSC activation. Taken together, our data illustrate a novel role for Aggfl in regulating hepatic inflammation and provide insights on the development of interventional strategies against cirrhosis.展开更多
目的研究超声造影联合hPygo2、人G补缀FHA域血管生成因子1(angiogenic factor with G and FHA domains 1,AGGF1)水平检测老年宫颈癌患者术后疗效。方法选取126例行手术治疗的老年宫颈癌患者作为研究对象,根据患者术后疗效分为有效组和...目的研究超声造影联合hPygo2、人G补缀FHA域血管生成因子1(angiogenic factor with G and FHA domains 1,AGGF1)水平检测老年宫颈癌患者术后疗效。方法选取126例行手术治疗的老年宫颈癌患者作为研究对象,根据患者术后疗效分为有效组和无效组,两组患者均行超声造影检测,并检测组织中hPygo2、AGGF1的表达情况,比较两组患者术后宫颈癌组织的血流灌注参数,并对影响术后疗效的相关因素进行单因素和Logistic回归分析,探讨影响术后疗效的独立影响因素,以及超声造影与hPygo2、AGGF1水平间的相互关系。结果有效组患者术前AT、TTP显著高于无效组,而PI显著低于无效组(P<0.05)。有效组患者宫颈癌组织中hPygo2、AGGF1表达水平显著高于无效组(P<0.05)。患者肿瘤大小、组织hPygo2和AGGF1表达水平以及影像结果均是影响术后疗效的危险因素。组织hPygo2和AGGF1表达水平、AT、TTP相互之间存在正相关性,均与PI呈现负相关。结论hPygo2、AGGF1在宫颈癌组织高水平表达,而超声造影可有效反应肿瘤血流灌注状态。三者之间存在显著相关性,联合检测可有效反应术后疗效。展开更多
目的:探究抗AGGF1中和抗体(RDD-Ab),RDD-Ab + 抗CTLA-4抗体联合治疗对小鼠黑色素瘤的治疗作用。方法:合成AGGF1的GTFQRDDAPASVHSE肽并制备多克隆中和抗体(RDD-Ab)。为了评估RDD-Ab对血管生成活性和黑色素瘤生长的影响,我们实施了小管生...目的:探究抗AGGF1中和抗体(RDD-Ab),RDD-Ab + 抗CTLA-4抗体联合治疗对小鼠黑色素瘤的治疗作用。方法:合成AGGF1的GTFQRDDAPASVHSE肽并制备多克隆中和抗体(RDD-Ab)。为了评估RDD-Ab对血管生成活性和黑色素瘤生长的影响,我们实施了小管生成实验、迁移实验、细胞增殖实验、黑色素瘤细胞皮下移植性模型实验和免疫组化等实验。结果:实验结果显示,制备的RDD-Ab可以识别细胞中天然的AGGF1蛋白和过表达的AGGF1蛋白。RDD-Ab可显著抑制血管内皮细胞小管形成、迁移和增殖。与IgG对照组相比,RDD-Ab治疗显著减缓黑色素瘤生长,RDD-Ab + CTLA-4抗体联合治疗时肿瘤生长速度最慢。免疫组化实验也表明,RDD-Ab显著减少瘤内微血管生成与肿瘤细胞增殖,同时,联合治疗可显著增加瘤内CD4+和CD8+淋巴细胞的浸润。结论:RDD-Ab可在体外抑制血管内皮细胞的血管新生功能,具有高效的黑色素瘤生长抑制作用,RDD-Ab + CTLA-4联合治疗黑色素瘤效果更佳(显著增加瘤内CD4+和CD8+淋巴细胞的浸润),这为未来黑色素瘤的临床干预提供了一种新的潜在治疗方案。Objective: To investigate the therapeutic effect of neutralizing antibody (against AGGF1, RDD-Ab), RDD-Ab + CTLA-4 therapy on mouse melanoma. Methods: Synthesize GTFQRDAPASVHSE peptide of AGGF1 and prepare polyclonal neutralizing antibody (RDD-Ab). In order to evaluate the effects of RDD-Ab on angiogenesis and melanoma growth, we conducted tube formation, migration, cell proliferation, subcutaneous melanoma cell transplantation model and immunohistochemistry (IHC). Results: RDD-Ab can recognize both natural AGGF1 protein and overexpressed AGGF1 protein in cells. The experimental results showed that RDD-Ab significantly inhibits the formation, migration, and proliferation of endothelial cell tubules. Compared with the IgG control group, RDD-Ab significantly slowed down the growth of melanoma. IHC experiments showed that RDD-Ab significantly suppressed tumor angiogenesis and proliferation. The combination therapy of RDD-Ab + CTLA-4 antibody has the slowest tumor growth rate, and the combination therapy increases the infiltration of CD4+ and CD8+ lymphocytes robustly in solid tumors. Conclusion: RDD-Ab can inhibit the angiogenesis function of endothelial cells in vitro and has a highly effective inhibitory effect on melanoma growth has an efficient inhibitory effect on melanoma growth, and the combined treatment with CTLA-4 antibody is more effective. This provides a new potential treatment option for clinical intervention of melanoma in the future.展开更多
目的:探究AGGF1预处理的EPCs对肾IRI的治疗作用。方法:用淋巴细胞分离液(histopaque-1083)离心分离出单个核细胞层,分离的单个核细胞(Bone marrow mononuclear cells, MNCs)进行鉴定(Dil-ac-LDL和FITC-UEA-1染色)后用分离纯化的AGGF1蛋...目的:探究AGGF1预处理的EPCs对肾IRI的治疗作用。方法:用淋巴细胞分离液(histopaque-1083)离心分离出单个核细胞层,分离的单个核细胞(Bone marrow mononuclear cells, MNCs)进行鉴定(Dil-ac-LDL和FITC-UEA-1染色)后用分离纯化的AGGF1蛋白预处理(0.5 μg/mL,洗涤后尾静脉注射) 12 h,之后进行小鼠细胞治疗。小鼠分Sham组、生理盐水组(Saline组,I/R小鼠)、EPCs组(移植EPCs,I/R小鼠)、AGGF1-EPCs组(移植AGGF1蛋白预处理的EPCs,I/R小鼠)共4组,为了评估AGGF1预处理的EPCs植入疗法对肾IRI的影响,我们实施了免疫荧光实验、免疫组化和ELISA等实验。结果:实验结果显示,MNCs来源的EPCs呈现Dil-ac-LDL和FITC-UEA-1阳性。ELISA实验结果显示,AGGF1-EPCs组小鼠的尿素氮水平(BUN),肌酐(Creatine)与急性肾损伤标志物NGAL水平均较Saline组、EPCs组显著下降,同时,免疫组化分析也显示AGGF1-EPCs组小鼠肾脏的F4/80较Saline组、EPCs组显著下降。此外,血清IL-1β,TNF-α的检测结果也显示,炎症因子(IL-1β, TNF-α)在AGGF1-EPCs组小鼠的中表达最低。结论:AGGF1预处理的EPCs植入疗法可以显著降低缺血再灌注引起的急性肾损伤与炎症反应,对IRI具有良好的改善保护作用,这为未来肾IR的临床干预提供了一种新的潜在治疗方案。Objective: To explore the therapeutic effect of AGGF1 primed-EPCs on renal ischemia-reperfusion injury (IRI). Methods: We centrifuge and separate the bone marrow mononuclear cells (MNCs) using histopaque-1083, and identify the MNCs with Dil-ac-LDL and FITC-UEA-1 staining. After pretreatment with purified AGGF1 protein (0.5 μg/mL), EPCs were washed and injected into the C57BL/6J mice via tail vein. The mice were divided into four groups: Sham group, Saline group (I/R mice), EPCs group (transplanted EPCs, I/R mice), and AGGF1-EPCs group (EPCs pretreated with AGGF1 protein, I/R mice). To evaluate the effect of EPCs implantation on renal IRI, we carried out western blot, ELISA, and immunohistochemistry experiments. Results: Our results showed that EPCs derived from MNCs exhibited Dil-ac-LDL and FITC-UEA-1 positive. The ELISA results showed that the levels of urea nitrogen (BUN), creatinine and acute kidney injury marker NGAL in the AGGF1-EPCs group mice were significantly lower than those in the Saline group and EPCs group. At the same time, immunohistochemical analysis also showed that the NGAL levels and F4/80 in the kidneys of AGGF1-EPCs group mice were significantly lower than those in the Saline group and EPCs group. In addition, we also observed that the inflammatory factors IL-1β, TNF-α were significantly reduced in the AGGF1-EPCs group of mice. Conclusion: The implantation therapy of AGGF1 primed-EPCs significantly reduce acute renal injury and inflammatory response caused by ischemia-reperfusion. This provides a new potential treatment for clinical intervention of renal IR.展开更多
Angiogenic factor with G-patch and FHA domains 1(AGGF1) exhibits a dynamic distribution from the nucleus to the cytoplasm in endothelial cells during angiogenesis, but the biological significance and underlying mechan...Angiogenic factor with G-patch and FHA domains 1(AGGF1) exhibits a dynamic distribution from the nucleus to the cytoplasm in endothelial cells during angiogenesis, but the biological significance and underlying mechanism of this nucleocytoplasmic transport remains unknown. Here, we demonstrate that the dynamic distribution is essential for AGGF1 to execute its angiogenic function. To search the structural bases for this nucleocytoplasmic transport, we characterized three potential nuclear localization regions, one potential nuclear export region, forkhead-associated(FHA), and G-patch domains to determine their effects on nucleocytoplasmic transport and angiogenesis, and we show that AGGF1 remains intact during the dynamic subcellular distribution and the region from 260 to 288 amino acids acts as a signal for its nuclear localization. The distribution of AGGF1 in cytoplasm needs both FHA domain and 14-3-3α/β. Binding of AGGF1 via FHA domain to 14-3-3α/β is required to complete the transport. Thus, we for the first time established structural bases for the nucleocytoplasmic transport of AGGF1 and revealed that the FHA domain of AGGF1 is essential for its nucleocytoplasmic transport and angiogenesis.展开更多
文摘目的:探讨AGGF1(angiogenic factor with G and FHA domains 1)在乳腺癌中的表达及其与乳腺癌患者预后的意义。方法:利用免疫组织化学方法检测110例乳腺癌组织及配对癌旁正常组织AGGF1蛋白的表达,并分析其与临床病理指标的关系及对患者预后的影响。结果:在乳腺癌组织中,AGGF1蛋白阳性45例(41%),AGGF1蛋白阴性65例(59%);配对癌旁正常组织中,AGGF1蛋白阳性15例(13.6%),AGGF1蛋白阴性95例(86.4%);AGGF1在乳腺癌组织的表达明显高于配对癌旁正常组织,差异有统计学意义(P<0.05)。AGGF1蛋白表达与患者年龄、肿瘤大小、TNM分期、淋巴结转移等无相关性(P>0.05);AGGF1蛋白表达与ER,PR,HER-2,增殖指数(Ki-67)等有相关性(P<0.05)。生存分析显示,AGGF1蛋白阳性表达患者的无病生存期(disease-free survival,DFS)与总生存期(overall-survival,OS)明显差于AGGF1蛋白阴性表达者,差异有统计学意义(P<0.05)。多因素COX比例风险回归模型分析发现:AGGF1蛋白阳性表达与乳腺癌患者的预后相关,为预后的独立预测因子。结论:在乳腺癌组织中,AGGF1蛋白阳性表达,与患者不良预后相关,可作为乳腺癌患者预后预测的指标,也有可能为潜在的治疗靶点。
基金supported,in part, by grants from the Natural Science Foundation of China (81402550)the Natural Science Foundation of Jiangsu Province (BK20140906)+2 种基金the Natural Science Foundation of Jiangsu Higher Education Institutions(14KJB310007)the Science & Technology Development Foundation of Nanjing Medical University (2013NJMU015)funding from Jiangsu Jiankang Vocational University (JK201405)
文摘Liver injury represents a continuum of pathophysiological processes involving a complex interplay between hepatocytes, macrophages, and hepatic stellate cells. The mechanism whereby these intercellular interactions contribute to liver injury and fibrosis is not completely understood. We report here that angiogenic factor with G patch and FHA domains 1(Aggfl) was downregulated in the livers of cirrhotic patients compared to healthy controls and in primary hepatocytes in response to carbon tetrachloride(CC14) stimulation. Overexpression of Aggfl attenuated macrophage chemotaxis. Aggfl interacted with NF-κB to block its binding to the Ccl2 gene promoter and repressed Ccl2 transcription in hepatocytes. Macrophages cultured in the conditioned media collected from Aggfloverexpressing hepatocytes antagonized HSC activation. Taken together, our data illustrate a novel role for Aggfl in regulating hepatic inflammation and provide insights on the development of interventional strategies against cirrhosis.
文摘目的研究超声造影联合hPygo2、人G补缀FHA域血管生成因子1(angiogenic factor with G and FHA domains 1,AGGF1)水平检测老年宫颈癌患者术后疗效。方法选取126例行手术治疗的老年宫颈癌患者作为研究对象,根据患者术后疗效分为有效组和无效组,两组患者均行超声造影检测,并检测组织中hPygo2、AGGF1的表达情况,比较两组患者术后宫颈癌组织的血流灌注参数,并对影响术后疗效的相关因素进行单因素和Logistic回归分析,探讨影响术后疗效的独立影响因素,以及超声造影与hPygo2、AGGF1水平间的相互关系。结果有效组患者术前AT、TTP显著高于无效组,而PI显著低于无效组(P<0.05)。有效组患者宫颈癌组织中hPygo2、AGGF1表达水平显著高于无效组(P<0.05)。患者肿瘤大小、组织hPygo2和AGGF1表达水平以及影像结果均是影响术后疗效的危险因素。组织hPygo2和AGGF1表达水平、AT、TTP相互之间存在正相关性,均与PI呈现负相关。结论hPygo2、AGGF1在宫颈癌组织高水平表达,而超声造影可有效反应肿瘤血流灌注状态。三者之间存在显著相关性,联合检测可有效反应术后疗效。
文摘目的:探究抗AGGF1中和抗体(RDD-Ab),RDD-Ab + 抗CTLA-4抗体联合治疗对小鼠黑色素瘤的治疗作用。方法:合成AGGF1的GTFQRDDAPASVHSE肽并制备多克隆中和抗体(RDD-Ab)。为了评估RDD-Ab对血管生成活性和黑色素瘤生长的影响,我们实施了小管生成实验、迁移实验、细胞增殖实验、黑色素瘤细胞皮下移植性模型实验和免疫组化等实验。结果:实验结果显示,制备的RDD-Ab可以识别细胞中天然的AGGF1蛋白和过表达的AGGF1蛋白。RDD-Ab可显著抑制血管内皮细胞小管形成、迁移和增殖。与IgG对照组相比,RDD-Ab治疗显著减缓黑色素瘤生长,RDD-Ab + CTLA-4抗体联合治疗时肿瘤生长速度最慢。免疫组化实验也表明,RDD-Ab显著减少瘤内微血管生成与肿瘤细胞增殖,同时,联合治疗可显著增加瘤内CD4+和CD8+淋巴细胞的浸润。结论:RDD-Ab可在体外抑制血管内皮细胞的血管新生功能,具有高效的黑色素瘤生长抑制作用,RDD-Ab + CTLA-4联合治疗黑色素瘤效果更佳(显著增加瘤内CD4+和CD8+淋巴细胞的浸润),这为未来黑色素瘤的临床干预提供了一种新的潜在治疗方案。Objective: To investigate the therapeutic effect of neutralizing antibody (against AGGF1, RDD-Ab), RDD-Ab + CTLA-4 therapy on mouse melanoma. Methods: Synthesize GTFQRDAPASVHSE peptide of AGGF1 and prepare polyclonal neutralizing antibody (RDD-Ab). In order to evaluate the effects of RDD-Ab on angiogenesis and melanoma growth, we conducted tube formation, migration, cell proliferation, subcutaneous melanoma cell transplantation model and immunohistochemistry (IHC). Results: RDD-Ab can recognize both natural AGGF1 protein and overexpressed AGGF1 protein in cells. The experimental results showed that RDD-Ab significantly inhibits the formation, migration, and proliferation of endothelial cell tubules. Compared with the IgG control group, RDD-Ab significantly slowed down the growth of melanoma. IHC experiments showed that RDD-Ab significantly suppressed tumor angiogenesis and proliferation. The combination therapy of RDD-Ab + CTLA-4 antibody has the slowest tumor growth rate, and the combination therapy increases the infiltration of CD4+ and CD8+ lymphocytes robustly in solid tumors. Conclusion: RDD-Ab can inhibit the angiogenesis function of endothelial cells in vitro and has a highly effective inhibitory effect on melanoma growth has an efficient inhibitory effect on melanoma growth, and the combined treatment with CTLA-4 antibody is more effective. This provides a new potential treatment option for clinical intervention of melanoma in the future.
文摘目的:探究AGGF1预处理的EPCs对肾IRI的治疗作用。方法:用淋巴细胞分离液(histopaque-1083)离心分离出单个核细胞层,分离的单个核细胞(Bone marrow mononuclear cells, MNCs)进行鉴定(Dil-ac-LDL和FITC-UEA-1染色)后用分离纯化的AGGF1蛋白预处理(0.5 μg/mL,洗涤后尾静脉注射) 12 h,之后进行小鼠细胞治疗。小鼠分Sham组、生理盐水组(Saline组,I/R小鼠)、EPCs组(移植EPCs,I/R小鼠)、AGGF1-EPCs组(移植AGGF1蛋白预处理的EPCs,I/R小鼠)共4组,为了评估AGGF1预处理的EPCs植入疗法对肾IRI的影响,我们实施了免疫荧光实验、免疫组化和ELISA等实验。结果:实验结果显示,MNCs来源的EPCs呈现Dil-ac-LDL和FITC-UEA-1阳性。ELISA实验结果显示,AGGF1-EPCs组小鼠的尿素氮水平(BUN),肌酐(Creatine)与急性肾损伤标志物NGAL水平均较Saline组、EPCs组显著下降,同时,免疫组化分析也显示AGGF1-EPCs组小鼠肾脏的F4/80较Saline组、EPCs组显著下降。此外,血清IL-1β,TNF-α的检测结果也显示,炎症因子(IL-1β, TNF-α)在AGGF1-EPCs组小鼠的中表达最低。结论:AGGF1预处理的EPCs植入疗法可以显著降低缺血再灌注引起的急性肾损伤与炎症反应,对IRI具有良好的改善保护作用,这为未来肾IR的临床干预提供了一种新的潜在治疗方案。Objective: To explore the therapeutic effect of AGGF1 primed-EPCs on renal ischemia-reperfusion injury (IRI). Methods: We centrifuge and separate the bone marrow mononuclear cells (MNCs) using histopaque-1083, and identify the MNCs with Dil-ac-LDL and FITC-UEA-1 staining. After pretreatment with purified AGGF1 protein (0.5 μg/mL), EPCs were washed and injected into the C57BL/6J mice via tail vein. The mice were divided into four groups: Sham group, Saline group (I/R mice), EPCs group (transplanted EPCs, I/R mice), and AGGF1-EPCs group (EPCs pretreated with AGGF1 protein, I/R mice). To evaluate the effect of EPCs implantation on renal IRI, we carried out western blot, ELISA, and immunohistochemistry experiments. Results: Our results showed that EPCs derived from MNCs exhibited Dil-ac-LDL and FITC-UEA-1 positive. The ELISA results showed that the levels of urea nitrogen (BUN), creatinine and acute kidney injury marker NGAL in the AGGF1-EPCs group mice were significantly lower than those in the Saline group and EPCs group. At the same time, immunohistochemical analysis also showed that the NGAL levels and F4/80 in the kidneys of AGGF1-EPCs group mice were significantly lower than those in the Saline group and EPCs group. In addition, we also observed that the inflammatory factors IL-1β, TNF-α were significantly reduced in the AGGF1-EPCs group of mice. Conclusion: The implantation therapy of AGGF1 primed-EPCs significantly reduce acute renal injury and inflammatory response caused by ischemia-reperfusion. This provides a new potential treatment for clinical intervention of renal IR.
基金This work was supported by grants from the National Natural Science Foundation of China(30730047,81070262,81130003 and 81630034).
文摘Angiogenic factor with G-patch and FHA domains 1(AGGF1) exhibits a dynamic distribution from the nucleus to the cytoplasm in endothelial cells during angiogenesis, but the biological significance and underlying mechanism of this nucleocytoplasmic transport remains unknown. Here, we demonstrate that the dynamic distribution is essential for AGGF1 to execute its angiogenic function. To search the structural bases for this nucleocytoplasmic transport, we characterized three potential nuclear localization regions, one potential nuclear export region, forkhead-associated(FHA), and G-patch domains to determine their effects on nucleocytoplasmic transport and angiogenesis, and we show that AGGF1 remains intact during the dynamic subcellular distribution and the region from 260 to 288 amino acids acts as a signal for its nuclear localization. The distribution of AGGF1 in cytoplasm needs both FHA domain and 14-3-3α/β. Binding of AGGF1 via FHA domain to 14-3-3α/β is required to complete the transport. Thus, we for the first time established structural bases for the nucleocytoplasmic transport of AGGF1 and revealed that the FHA domain of AGGF1 is essential for its nucleocytoplasmic transport and angiogenesis.